Loading
Glasdegib is a hedgehog-pathway pill that, with low-dose chemotherapy, extends survival in older AML patients who cannot have intensive treatment; it has largely been displaced by venetoclax combinations.
Glasdegib inhibits smoothened (SMO), reducing hedgehog signalling in leukaemic stem cells, and is combined with low-dose cytarabine for newly diagnosed AML in adults aged 75 or over or unfit for intensive chemotherapy. In BRIGHT AML 1003 the combination gave a median overall survival of 8.8 versus 4.9 months with low-dose cytarabine alone, leading to US approval in 2018 and EU approval in 2020. The BRIGHT AML 1019 trials, which added glasdegib to intensive chemotherapy or azacitidine backbones, were negative. In the same period venetoclax with azacitidine became the preferred regimen for unfit AML, so glasdegib is now rarely chosen. Muscle spasms, dysgeusia and alopecia are class hedgehog-inhibitor effects. For a newcomer, glasdegib proved that a hedgehog pill could extend survival in older AML but was overtaken by a better combination.
Inhibits SMO, reducing hedgehog signalling in leukaemic stem cells; combined with low-dose cytarabine. Connects to Smoothened (hedgehog pathway).
1.Glasdegib slips into a pocket on Smoothened (hedgehog pathway).
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA647 · SMC advice: glasdegib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Newly diagnosed AML in adults ≥75 or unfit for intensive chemotherapy, with low-dose cytarabine |
| EU | 2020 | Same |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Glasdegib" OR ABSTRACT:"Glasdegib" OR TITLE:"Daurismo" OR ABSTRACT:"Daurismo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Glasdegib, not a curated reading list.
Shares A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia, Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares Hedgehog pathway inhibitors, Small-molecule kinase inhibitors.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares Hedgehog pathway inhibitors, Smoothened (hedgehog pathway).
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.